Janssen Israel and Sheba ARC

Janssen Israel and Sheba ARC, we want to be.an innovation hub set up by Sheba Medical Center to develop and promote digital health Solutions

“ Our strategy, as is Sheba's is to lead by innovation. We're a very patient-centric company with the goal to 'go beyond the pill' - adding value to our customers and maximizing treatment results.”

As the pharmaceutical division of Johnson & Johnson, Janssen focuses on developing innovative molecules for patients in different therapeutic areas, to serve unmet medical needs. This aligns well with Sheba's position as one of the world's most digitally advanced hospitals.

The Sheba ARC Center (Accelerate, Redesign, Collaborate) brings together key players in digital medicine - physicians, researchers, start-ups, investors, and top-tier medical centers with the goal of redesigning healthcare.

“Our innovation room at ARC physically connects us to the main players there and encourages us all to collaborate”, said Clive Kaye, Managing Director for Janssen Israel.

"Our strategy - as is Sheba's - is to lead by innovation. We're a very patient-centric company with the goal to 'go beyond the pill' - adding value to our customers and maximizing treatment results”.

Janssen is partnering with Sheba in three key areas:

1. Supporting promising Israeli digital medicare solutions

2. Getting valuable insights into the patient's journey, using synthetic data

3. Being on-site at ARC to interact with the main ecosystem players

“Our partnership with Sheba consists in finding technological solutions, looking at the therapeutic areas where we wish to focus, plus working with researchers and technology partners-usually start-ups”, said Clive.

He adds: “We currently focus on some digital health projects including areas such as Psychiatry, Gastroenterology and Oncology”.

Janssen Conducts research using synthetic data provided by MDClone. Performing research while using such data makes it easier and simpler to locate any event along a patient's journey without having to worry about patients' privacy issues.

Professor Eyal Zimlichman, the Chief Medical Officer as well as the Chief Innovation Officer at Sheba, added: “Janssen was the first industry partner who we signed. We learned very quickly that they share our audacity about where we want to be."

READ THE FULL SHEBA ARC DIGITAL REPORT HERE

Share

Featured Articles

ICYMI: The potential of 5G and Europe’s technology gap

A week is a long time in tech, so here’s a round-up of Technology Magazine articles that have been starting conversations around the world

Oracle NetSuite’s SuiteWorld 2022 - Day 3 Highlights

Live from SuiteWorld 2022 - Technology Magazine shares the highlights from the third day of Oracle NetSuite’s event, in Las Vegas’ iconic Caesar’s Forum

Unlocking 5G’s potential with network slicing

As communication service providers look to find new revenue opportunities, we assess how network slicing could be the key to unlocking its potential

Global tech teams rewarded by post-pandemic performance

Digital Transformation

Oracle NetSuite’s SuiteWorld 2022 - highlights from Day 2

Data & Data Analytics

Sustainability and the CIO: how tech can save the world

Digital Transformation